FDA Clearance Tracker · P130008-S093
Inspire II Upper Airway Stimulator
Last checked: Nov 20, 2026Latest source record: Dec 16, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Dec 16, 2022
Approved
Time to decision
28 days
Received Nov 18, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130008-S093
- Device name
- Inspire II Upper Airway Stimulator
- Applicant
- Inspire Medical Systems
- Applicant location
- Maple Grove, MN
- Received
- Nov 18, 2022
- Decided
- Dec 16, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P130008
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Inspire® Upper Airway Stimulation (UAS). The device is indicated for use to treat a subset of patients with moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] of greater than or equal to 15 and less than or equal to 65). Inspire® UAS is used in adult patients 22 years of age and older who have been confirmed to fail or cannot tolerate positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BPAP] machines) and who do not have a complete concentric collapse at the soft palate level.PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as:1) Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night); or2) Unwillingness to use PAP (for example, a patient returns the PAP system after attempting to use it).Inspire® UAS is also indicated for use in patients between the ages of 18 and 21with moderate to severe OSA (15?AHI?65) who:1) Do not have complete concentric collapse at the soft palate level;2) Are contraindicated for, or not effectively treated by, adenotonsillectomy;3) Have been confirmed to fail, or cannot tolerate, PAP therapy despite attempts to improve compliance; and4) Have followed standard of care in considering all other alternative/adjunct therapies.
Source documents
Other decisions for Inspire Medical Systems
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Inspire Upper Airway Stimulation SystemPMA supplement
P130008-S090 · Decided Jun 8, 2023 · 234 days after receipt · Panel Track
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.